FDA Approved 6 New Oncology Indications in December 2022

FDA Approved 6 New Oncology Indications in December 2022

The US FDA approved six new indications for cancer management in December. This includes updated labeling for capecitabine tablets. Oral Capecitabine Label Update. Updated labeling was approved for capecitabine tablets (Xeloda®, Genentech, Inc.) under Project Renewal, an Oncology Center of Excellence initiative. Capecitabine is the...

FDA Approved 7 New Oncology Indications in October-November 2022
FDA Approved 6 New Oncology Indications in December 2022

FDA Approved 6 New Oncology Indications in December 2022

The US FDA approved six new indications for cancer management in December. This includes updated labeling for capecitabine tablets. Oral Capecitabine Label...

FDA Approved 7 New Oncology Indications in October-November 2022

FDA Approved 7 New Oncology Indications in October-November 2022

In October and November, the US FDA approved seven new indications for cancer management. This includes a new dosing regimen for an...
Survival Benefit with Low-Dose Nivolumab Regimen in Advanced SCCHN

Survival Benefit with Low-Dose Nivolumab Regimen in Advanced SCCHN

Based on improved survival and favorable toxicity profiles, immunotherapy with anti-PD-1 agents (pembrolizumab, nivolumab) has become the standard of care in recurrent/metastatic...
New Oncology Guidelines Worth Reading

New Oncology Guidelines Worth Reading

Recently, three new guidelines related to oncology have been issued by major European and American medical associations to help clinicians provide the...
New FDA Approvals for Cancer Treatment in September 2022

New FDA Approvals for Cancer Treatment in September 2022

In September, the US FDA approved five new indications for cancer management. Futibatinib for Metastatic Cholangiocarcinoma. Accelerated approval was granted for the...